Veradermics (MANE) Common Equity (2024 - 2026)

Veradermics' Common Equity history runs 3 years deep, the most recent figure standing at $390.6 million for Q1 2026.

• Quarterly Common Equity rose 743.91% year-over-year to $390.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $390.6 million (up 743.91% YoY) and the FY2024 annual result came in at -$48.5 million, changed N/A from the prior year.
• Common Equity was $390.6 million for Q1 2026 at Veradermics, up from -$60.7 million in the prior quarter.
• Across five years, Common Equity topped out at $390.6 million in Q1 2026 and bottomed at -$60.7 million in Q1 2025.
• A 3-year average of $93.8 million and a median of -$48.5 million in 2024 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 743.91% in 2026, while the deepest fall reached 743.91% in 2026.
• Veradermics' Common Equity stood at -$48.5 million in 2024, then fell by 25.14% to -$60.7 million in 2025, then surged by 743.91% to $390.6 million in 2026.
• Business Quant data shows MANE's Common Equity at $390.6 million in Q1 2026, -$60.7 million in Q1 2025, and -$48.5 million in Q4 2024.